What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Surgery
The scientist’s investigation covers issues in Hepatocellular carcinoma, Internal medicine, Radiology, Cirrhosis and Gastroenterology.
His work carried out in the field of Hepatocellular carcinoma brings together such families of science as Carcinoma, Surgery and Liver transplantation, Milan criteria.
Fabio Piscaglia works mostly in the field of Internal medicine, limiting it down to topics relating to Oncology and, in certain cases, Gold standard.
His Radiology course of study focuses on Chronic liver disease and Hepatitis.
His Cirrhosis study also includes fields such as
- Hepatitis C most often made with reference to Liver biopsy,
- Lesion that connect with fields like Embolization.
His Gastroenterology study incorporates themes from Surgical oncology, Resection, Propensity score matching and Risk factor.
His most cited work include:
- EASL-EORTC clinical practice guidelines : management of hepatocellular carcinoma (4279 citations)
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (1199 citations)
- Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. (752 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of study are Internal medicine, Hepatocellular carcinoma, Radiology, Gastroenterology and Cirrhosis.
His Internal medicine research incorporates elements of Oncology and Cardiology.
His Hepatocellular carcinoma research includes themes of Carcinoma, Surgery and Milan criteria.
His Contrast-enhanced ultrasound, Ultrasound, Magnetic resonance imaging, Elastography and Ultrasonography investigations are all subjects of Radiology research.
His Gastroenterology study frequently draws connections to other fields, such as Hepatitis C.
His Cirrhosis research integrates issues from Liver biopsy and Pathology.
He most often published in these fields:
- Internal medicine (45.75%)
- Hepatocellular carcinoma (41.30%)
- Radiology (29.15%)
What were the highlights of his more recent work (between 2018-2021)?
- Hepatocellular carcinoma (41.30%)
- Internal medicine (45.75%)
- Oncology (15.18%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Hepatocellular carcinoma, Internal medicine, Oncology, Sorafenib and Radiology.
His research investigates the link between Hepatocellular carcinoma and topics such as Carcinoma that cross with problems in Survival rate.
Internal medicine is frequently linked to Gastroenterology in his study.
Fabio Piscaglia has researched Oncology in several fields, including Cabozantinib, Multivariate analysis, Regorafenib and Nivolumab, Immunotherapy.
His work on Lenvatinib as part of his general Sorafenib study is frequently connected to Tyrosine kinase, thereby bridging the divide between different branches of science.
His work in Radiology tackles topics such as Cirrhosis which are related to areas like Surgery.
Between 2018 and 2021, his most popular works were:
- Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. (38 citations)
- Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis. (33 citations)
- Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. (28 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
Fabio Piscaglia mainly focuses on Hepatocellular carcinoma, Internal medicine, Oncology, Sorafenib and Cirrhosis.
The various areas that Fabio Piscaglia examines in his Hepatocellular carcinoma study include Cancer, Carcinoma and Ultrasound.
His research on Internal medicine often connects related topics like Gastroenterology.
His Oncology research focuses on subjects like Nivolumab, which are linked to Cabozantinib, Ipilimumab, Safety profile and Pembrolizumab.
His studies deal with areas such as Phenotype and Adverse effect as well as Sorafenib.
He combines subjects such as Magnetic resonance imaging, Radiology and Contrast-enhanced ultrasound with his study of Lesion.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
